Sarepta veteran O’Neill becomes CEO at Editas
Plus Slapak retires from Vor, and updates from Harbour, Citius and more
Editas Medicine Inc. (NASDAQ:EDIT) said Gilmore O’Neill was taking over as CEO, effective June 1. O’Neill is the company’s fourth chief executive and the third it’s had since 2019 when the first, Katrine Bosley, resigned. The company’s second CEO, Cynthia Collins, lasted less than two years; and its third, James Mullen, a year. O’Neill was EVP of R&D and CMO at Sarepta Therapeutics Inc. (NASDAQ:SRPT) and held several leadership roles at Biogen Inc. (NASDAQ:BIIB) over a 15-year period. Editas shares fell $2.10 (11%) to $16.67.
Christopher Slapak will retire as CMO from Vor Biopharma Inc. (NASDAQ:VOR), a cell and genome engineering company. Slapak joined Vor in 2019 as interim CMO, having held several roles at Eli Lilly and Co. (NYSE:LLY) over 20 years. VOR33, the company’s lead cell therapy, is in Phase I/II for acute myelogenous leukemia. A search for a successor has begun...